

JAMA Dermatology | Consensus Statement

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss

An International Modified Delphi Consensus Statement

Yagiz Matthew Akiska, BSE; Paradi Mirmirani, MD; Ingrid Roseborough, MD; Erin Mathes, MD; Tina Bhutani, MD; Andrew Ambrosy, MD; Crystal Aguh, MD; Wilma Bergfeld, MD; Valerie D. Callender, MD; Leslie Castelo-Soccio, MD, PhD; George Cotsarelis, MD; Brittany Gareth Craiglow, MD; Nisha S. Desai, MD; Isabella Doche, MD, PhD; Bruna Duque-Estrada, MD; Dirk M. Elston, MD; Carolyn Goh, MD; Lynne J. Goldberg, MD; Ramon Grimalt, MD, PhD; Ali Jabbari, MD, PhD; Victoria Jolliffe, MD; Brett A. King, MD, PhD; Charlotte LaSenna, MD; Yolanda Lenzy, MD, MPH; Jenna C. Lester, MD; Nino Lortkipanidze, MD, PhD; Kristen I. Lo Sicco, MD; Amy McMichael, MD; Nekma Meah, MBChB; Natasha Mesinkovska, MD, PhD; Mariya Miteva, MD; Arash Mostaghimi, MD, MPA, MPH; Yuliya Ovcharenko, MD, PhD; Melissa Piliang, MD; Bianca Maria Piraccini, MD, PhD; Adriana Rakowska, MD, PhD; Kimberly S. Salkey, MD; Adriana Schmidt, MD; Jerry Shapiro, MD; Cathryn Sibbald, MD, MSc; Rodney Sinclair, MBBS, MD; Poonkiat Suchonwanit, MD; Susan Taylor, MD; Antonella Tosti, MD; Sergio Vañó-Galván, MD, PhD; Dmitri Robert Wall, MB, BCh BAO, MSc; Jennifer M. Fu, MD

IMPORTANCE The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking.

OBJECTIVE To create an expert consensus statement for LDOM prescribing for patients with hair loss.

EVIDENCE REVIEW The current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale.

FINDINGS Over 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus.

CONCLUSIONS AND RELEVANCE This international expert consensus statement regarding the off-label prescribing of LDOM for patients with hair loss can help guide clinical practice until more data emerge. Hair loss experts with experience treating pediatric patients were underrepresented on this expert panel. Future research should investigate best practices for LDOM use in pediatric patients. Other critical topics for further investigation include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minoxidil and sublingual minoxidil. As additional evidence-based data emerge, these recommendations should be updated.

JAMA Dermatol. doi:10.1001/jamadermatol.2024.4593
Published online November 20, 2024.

[+ Supplemental content](#)

[+ CME at \[jamacmelookup.com\]\(http://jamacmelookup.com\)](#)

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Jennifer M. Fu, MD, Department of Dermatology, University of California, San Francisco, 1701 Divisadero St, 4th Floor, San Francisco, CA 94115 (jennifer.fu2@ucsf.edu).

Hair loss significantly impacts patients' quality of life, and it may be nonscarring or scarring. Etiologically, hair loss may be hereditary (androgenetic alopecia [AGA]); related to age; congenital (hair shaft disorders); traction induced; inflammatory (primary scarring alopecia); autoimmune (alopecia areata); or secondary to medical, surgical, or emotional stressors (telogen effluvium), infection (tinea capitis), and certain medications including cancer therapies.¹

Topical minoxidil is approved by the US Food and Drug Administration (FDA) as an over-the-counter drug designed to treat male patients with AGA (minoxidil, 5% solution, or minoxidil, 5% foam, twice daily) and female patients with AGA (minoxidil, 2% solution, twice daily, or minoxidil, 5% foam, once daily).^{2,3} It is also frequently prescribed off-label for other types of hair loss in children and adults.²⁻⁶ Common adverse effects include transient shedding with initiation, hypertrichosis, and contact dermatitis, most commonly secondary to nonactive formulary ingredients, such as propylene glycol.²

Minoxidil, a potent peripheral vasodilator, was originally approved by the FDA in 1979 as an oral agent for patients with severe refractory hypertension with antihypertensive dosing ranging from 10 mg to 40 mg daily.^{6,7} Interestingly, a significant adverse effect of oral minoxidil was hypertrichosis, leading to the development of topical minoxidil as a hair growth agent in the 1980s.

Minoxidil exerts its effects via various proposed pathways: (1) a vasodilator acting on adenosine triphosphate-sensitive potassium channels, (2) an anti-inflammatory agent, (3) inducer of the Wnt/ β -catenin signaling pathway, (3) a 5- α reductase inhibitor and antiandrogen, and (4) an anagen extender.⁶ Topical minoxidil is converted into its active form, minoxidil sulfate, via sulfotransferase enzyme activity in the outer root sheath of hair follicles, and oral minoxidil is absorbed in the gastrointestinal tract and converted to its activated sulfated form in the liver.⁶ The systemic absorption of topical minoxidil is negligible, well below the minimum level of 20.0 ng per millimeter, at which hemodynamic changes in blood pressure have been documented.² Oral minoxidil reaches peak levels in plasma within an hour, has a half-life of 3 to 4 hours, and is excreted by the kidneys within 12 to 20 hours.⁶

Oral minoxidil is not a first-line antihypertensive agent due to the risk for fluid retention, tachycardia, and other potential adverse effects, such as pericardial and pleural effusion, cardiac tamponade, and angina pectoris, with antihypertensive dosing.⁷ However, a growing number of research groups have reported on the off-label use of low-dose oral minoxidil (LDOM), ranging from 0.25 mg to 5 mg daily, as a safe and effective treatment option for male and female patients with AGA, age-related patterned thinning, traction alopecia, alopecia areata, telogen effluvium, scarring, and other forms of hair loss,^{4,5,8-22} though some serious adverse effects have been reported.^{23,24} This correlates with an increased demand for LDOM prescriptions in recent years.¹⁶ As the current data on LDOM initiation and monitoring for hair loss are limited, there is a pressing need for an expert consensus-based statement for common use to maximize hair growth and minimize cardiovascular and other adverse effects.

Methods

Delphi Survey Design

The Delphi technique is an iterative process that collates anonymous expert opinions and provides controlled feedback over mul-

Key Points

Question What are the best practice recommendations for off-label use of low-dose oral minoxidil (LDOM) for patients with hair loss?

Findings A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi exercise and reached consensus on 76 items, including diagnoses for which LDOM may provide benefit, indications for when LDOM is preferred to topical minoxidil, adult and adolescent use, contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation.


Meaning LDOM is an increasingly popular off-label treatment for patients with hair loss; this international expert consensus statement on LDOM use for patients with hair loss can help inform clinical practice until high-quality evidence-based data emerge.

iple rounds to generate structured and unbiased consensus on topics of interest.²⁵ For this study, the current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed, topics of interest identified, and a modified Delphi consensus process created by the multidisciplinary Low-Dose Oral Minoxidil Initiation (LOMI) steering committee (hair loss/dermatology experts, J.M.F., P.M., I.R.; medical dermatology expert, T.B.; pediatric dermatology expert, E.M.; cardiology expert, A.A.; University of California, San Francisco [UCSF], Department of Dermatology summer research fellow and study coordinator, Y.M.A.). This study adhered to the Standards for Quality Improvement Reporting Excellence (SQUIRE) reporting guideline (Figure).²⁶ Survey distribution, from March 21, 2023, to January 22, 2024, and secure data storage were managed with the UCSF's Research Electronic Data Capture (REDCap) platform.²⁷ This study was exempted from review by the University of California, San Francisco institutional review board.

Dermatologists with hair loss expertise, identified by clinical experience, research activities, and participation in recognized professional societies, including the North American Hair Research Society, International Federation of Hair Research Societies, and World Congress for Hair Research, were invited via email to join the LOMI expert panel and engage in multiple survey rounds addressing LDOM safety, efficacy, dosing, and monitoring for treating patients with hair loss. Experts were encouraged to answer items based on their clinical expertise and experience with LDOM; relevant literature was provided for review. To minimize bias, individual expert responses were anonymous from all except the study coordinator (Y.M.A.). Based on consensus parameters set by prior Delphi studies, consensus for a LOMI item was defined as at least 70% of experts indicating agree or strongly agree on a 5-point Likert scale.²⁸⁻³⁴

The initial survey round included items that were non-Likert scale (demographic, open-ended, or multiple choice), as well as items requiring a Likert scale response (strongly disagree, disagree, neutral, agree, strongly agree; Figure). After each round, aggregated responses were reviewed by the multidisciplinary LOMI steering committee, and feedback was provided to the LOMI expert panel. When indicated, survey items were revised for clarification or to incorporate expert comments and submitted for expert review in subsequent rounds. In rounds 2, 3, and 4, survey items were calibrated

Figure. Low-Dose Oral Minoxidil Initiation Modified Delphi Consensus Process



^aItems that needed revision were reconsidered in subsequent rounds as single, multiple, and sometimes combined items.

to elicit Likert-only responses on items close to consensus. For rounds 2 and 3, close to consensus was defined as 60% to 69% of experts indicating agree or strongly agree on a 5-point Likert scale. For round 4, close to consensus was defined more stringently as 65% to 69% of experts indicating agree or strongly agree. Items achieving Likert scale consensus and not requiring further consideration were finalized and not reconsidered in subsequent rounds. Items that achieved at least 70% consensus but required further consider-

Table 1. Hair Loss Expert Panel Demographics

| Variable | No. (%) | |
|---|------------------|------------|
| | Round 1 | Rounds 2-4 |
| Experts invited, No. ^a | 73 | 44 |
| Experts participated, No. | 44 | 43 |
| Countries represented, No. ^b | 12 | 12 |
| Postresidency dermatology experience, median (IQR), y | 14.5 (10.3-27.5) | 15 (11-29) |
| Experience with LDOM, median (IQR), y | 5 (3-6) | 5 (3-6) |
| Patient care setting ^c | | |
| Academic institution | 34 (77.3) | 33 (76.7) |
| Private practice | 20 (45.5) | 20 (46.5) |
| Hospital-based specialty group | 7 (15.9) | 7 (16.2) |
| Public service | 5 (11.4) | 5 (11.6) |
| Managed care organization | 1 (2.3) | 1 (2.3) |
| Patient population treated ^c | | |
| Adults (≥18 y) | 43 (97.7) | 42 (97.6) |
| Adolescents (12-17 y) | 24 (54.5) | 24 (55.8) |
| Pediatric (<12 y) | 17 (38.6) | 17 (39.5) |

Abbreviation: LDOM, low-dose oral minoxidil.

^a Experts who fully completed the survey from the subsequent round were invited for the following rounds.

^b Countries represented included Australia, Brazil, Canada, Georgia, Ireland, Italy, Poland, Spain, Thailand, Ukraine, the UK, and the US.

^c Experts were able to indicate multiple patient care settings and/or populations treated.

ation, or did not achieve at least 70% consensus, were either revised or reconsidered in subsequent rounds or eliminated.

Results

Demographics of Expert Panel

Of 73 invited hair loss experts, 44 completed round 1 (Table 1). A total of 43 experts (98%), representing 12 countries, went on to complete rounds 2 through 4 of the modified Delphi process. LOMI experts who participated in all 4 rounds indicated a median (IQR) of 15 (11-29) years of postresidency dermatology experience and a median (IQR) of 5 (3-6) years of experience prescribing LDOM for patients with hair loss. Patient care settings were diverse, with many experts practicing in multiple settings, including 33 clinicians (76.7%) in academic institutions, 20 clinicians (46.5%) in private practice, 7 clinicians (16.2%) in hospital-based specialty groups, 5 clinicians (11.6%) in public service settings, and 1 clinician (2.3%) at a managed care organization. Forty-two clinicians (97.6%) reported treating adults with hair loss (defined as individuals 18 years and older); 24 clinicians (55.8%) reported treating adolescents with hair loss (defined as individuals aged between 12 and 17 years); and 17 clinicians (39.5%) reported treating pediatric patients with hair loss (defined as individuals younger than 12 years).

Delphi Survey Rounds

LOMI experts considered items throughout 4 rounds: the first round included 180 non-Likert scale and Likert scale items; the second round, 121 Likert scale items; the third round, 16 Likert scale items; and the fourth round, 11 Likert scale items (Figure). A total of 76 items

Table 2. Consensus Outcomes Regarding Who to Treat

| Item | Consensus reached, No. of experts (%) | Round No. |
|---|---------------------------------------|-----------|
| Patient populations for whom LDOM may be considered | | |
| Adult (≥18 y) | 40 (93.0) | 2 |
| Adolescent (12 to 17 y) | 37 (86.0) | 2 |
| Indications | | |
| Conditions for which LDOM may provide direct benefit | | |
| AGA | 42 (97.7) | 2 |
| Age-related patterned thinning | 42 (97.7) | 2 |
| Alopecia areata | 35 (81.4) | 2 |
| Telogen effluvium | 37 (86.0) | 2 |
| Traction alopecia | 34 (79.1) | 2 |
| Persistent chemotherapy-induced alopecia | 36 (83.7) | 2 |
| Endocrine therapy-induced alopecia | 36 (83.7) | 2 |
| Conditions for which LDOM may provide supportive benefit | | |
| Lichen planopilaris | 38 (88.4) | 2 |
| Frontal fibrosing alopecia | 38 (88.4) | 2 |
| Central centrifugal alopecia | 37 (86.0) | 2 |
| Fibrosing alopecia in a patterned distribution | 34 (79.1) | 2 |
| Cases when LDOM may be considered over topical minoxidil | | |
| Topical minoxidil is more expensive | 31 (70.5) | 1 |
| Topical minoxidil application is time-consuming or logistically challenging | 41 (93.2) | 1 |
| Topical minoxidil application results in undesirable product residue, hair texture change, or hair styling issues | 42 (95.5) | 1 |
| Topical minoxidil may exacerbate an inflammatory process of the scalp (eg, cicatricial alopecia or primary cutaneous dermatitis, such as seborrheic dermatitis, eczema, or psoriasis) | 41 (93.2) | 1 |
| Topical minoxidil has not been effective or has plateaued in efficacy | 40 (90.9) | 1 |
| Enhanced hypertrichosis is a desired effect (eg, transgender patient population) | 38 (86.4) | 1 |
| Contraindications for the use of LDOM | | |
| Ongoing other drug therapy with significant oral minoxidil interaction | 38 (86.4) | 1 |
| History of pericardial effusion/tamponade | 36 (81.8) | 1 |
| History of pericarditis | 32 (72.7) | 1 |
| Congestive heart failure | 34 (79.1) | 2 |
| History of pulmonary hypertension associated with mitral stenosis | 33 (76.7) | 2 |
| Pheochromocytoma | 32 (74.4) | 3 |
| Patients who are pregnant or breastfeeding | 42 (95.5) | 1 |
| Precautions for the use of LDOM | | |
| History of tachycardia or other arrhythmia | 36 (81.8) | 1 |
| Hypotension (blood pressure <90/60 mm Hg) | 34 (77.3) | 1 |
| Kidney function impairment | 38 (88.4) | 2 |
| Patients undergoing dialysis | 38 (88.4) | 2 |

Abbreviations: AGA, androgenetic alopecia; LDOM, low-dose oral minoxidil.

^a Items for which contraindication consensus was achieved were excluded from precaution consideration.

achieved final consensus, including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, adult and adolescent dosing, contraindications, precautions, baseline evaluation, monitoring, adjunctive

therapy, and specialty consultation. Consensus was not achieved on pediatric use and dosing or LDOM titration protocols (eTable in the [Supplement](#)).

Consensus Outcomes Regarding Who to Treat

Patient Populations

Consensus was reached in round 2 that LDOM treatment may be considered for adult and adolescent patients (40 [93.0%] and 37 [86.0%] experts agreed, respectively; [Table 2](#)). Whether LDOM may be considered for pediatric patients fell short of consensus in round 2 (ie, only 23 experts concurred [53.5%]; eTable in the [Supplement](#)).

Indications for LDOM Use

Strong consensus was reached that LDOM may provide direct benefit for AGA and age-related patterned thinning (42 [97.7%] and 42 [97.7%] experts agreed, respectively; [Table 2](#)). LOMI experts also concurred during round 2 that LDOM might provide direct benefit for other conditions in which follicular miniaturization or hair cycle disruption may be present, including 35 experts (81.4%) agreeing for alopecia areata, 37 experts (86.0%) for telogen effluvium, 34 experts (79.1%) for traction alopecia, 36 experts (83.7%) for persistent chemotherapy-induced alopecia, and 36 experts (83.7%) for endocrine therapy-induced alopecia. Consensus during round 2 was reached that LDOM may provide supportive benefit for the following forms of cicatricial alopecia: lichen planopilaris (38 experts [88.4%] agreed); frontal fibrosing alopecia (38 experts [88.4%] agreed); central centrifugal alopecia (37 [86.0%] agreed), and fibrosing alopecia in a patterned distribution (34 [79.1%] experts agreed). Diagnoses that did not reach consensus for either direct or supportive benefits from LDOM are detailed in the eTable in the [Supplement](#).

Choice of LDOM vs Topical Minoxidil

Consensus was reached during round 1 that LDOM may be favored over topical minoxidil when LDOM is less expensive (31 experts [70.5%] agreed); is more convenient (41 experts [93.2%] agreed); topical minoxidil causes styling issues, undesirable product residue, or hair texture change (42 experts [95.5%] agreed); when topical minoxidil coincides with scalp inflammation (whether secondary to cicatricial alopecia or a primary cutaneous dermatitis, such as seborrheic dermatitis, eczema, or psoriasis; 41 experts [93.2%] agreed); topical minoxidil results in an ineffective or plateaued response (40 experts [90.9%] agreed), or the desire for enhanced hypertrichosis (eg, transgender patient population) are relevant to the patient (38 [86.4%] experts agreed; [Table 2](#)).

Contraindications and Precautions

Consensus was achieved during rounds 1, 2, and 3 that the following should be considered contraindications for LDOM use: ongoing alternate drug therapy interacting significantly with oral minoxidil (38 experts [86.4%] agreed); history of pericardial effusion/tamponade (36 experts [81.8%] agreed); history of pericarditis (32 experts [72.7%] agreed); congestive heart failure (34 experts [79.1%] agreed); history of pulmonary hypertension associated with mitral stenosis (33 experts [76.7%] agreed); pheochromocytoma (32 experts [74.4%] agreed); and pregnancy or breastfeeding (42 experts [95.5%] agreed; [Table 2](#)).

LOMI experts reached consensus during rounds 1 and 2 that the following should be considered precautions for LDOM use: history of tachycardia or other arrhythmia (36 experts [81.8%] agreed); hypotension indicated by blood pressure level less than 90/60 mm Hg (34 experts [77.3%] agreed); kidney function impairment (38 experts [88.4%] agreed); and patients undergoing dialysis (38 experts [88.4%] agreed; Table 2).

Of note, items for which contraindication consensus was achieved were excluded from precaution considerations. Items that failed to reach consensus as either contraindications or precautions are detailed in the eTable in the Supplement. Consensus was reached on 2 items regarding minoxidil hypersensitivity in round 1, including the following: (1) "LDOM may be considered over topical minoxidil when topical minoxidil application results in skin irritation or allergy" and (2) "The following should be considered a contraindication for the use of LDOM: hypersensitivity to minoxidil" (43 [97.7%] and 39 [88.6%] experts agreed, respectively; eAppendix in the Supplement). However, on subsequent review, these statements were deemed vague regarding the type of allergy or hypersensitivity and route of administration of minoxidil and therefore were not included as final consensus outcomes.

Consensus Outcomes Regarding How to Treat

Specialty Consultation Before Prescribing LDOM

LOMI experts concurred during round 2 that specialty consultation with primary care or cardiology clinicians may be sought before prescribing LDOM (41 experts [95.3%] agreed), especially when potential precautions or contraindications are identified (39 [90.7%] and 42 [97.7%] experts agreed, respectively), or coordination of care is needed (41 experts [95.3%] agreed, respectively; Table 3).

Baseline Testing Before Prescribing LDOM

Consensus was reached during round 2 that, in the absence of precautions, baseline laboratory and electrocardiogram evaluation results are not routinely indicated (39 [90.7%] and 40 [93.0%] experts agreed, respectively; Table 3). In the presence of relevant precautions, baseline laboratory and electrocardiogram evaluation may be considered in consultation with a specialist (32 [74.4%] and 37 [86.0%] experts agreed, respectively).

LDOM Dosing Considerations

Consensus was achieved during round 2 that the following patient characteristics may inform the determination of starting dosing of LDOM: sex (33 experts [76.7%] concurred), age (for adults, 35 experts [81.4%] concurred; for adolescents, 36 experts concurred [83.7%]), hypertrichosis as either an undesirable or desirable effect (40 experts concurred [93.0%]), and the risk for systemic adverse effects (42 experts concurred [97.7%]; Table 3). Additionally, the severity of baseline hair loss was considered an important factor for determining the maximum dosages of LDOM during round 2 (32 experts [74.4%] concurred).

LOMI experts were asked about their typical dosing practices in round 1; these open-ended responses facilitated the creation of Likert scale items reintroduced in round 3 (Table 3). The most frequently prescribed LDOM starting doses and dosing ranges achieved consensus during rounds 3 and 4 for female adults (starting dose, 1.25 mg daily, and dosing range, 0.625 mg to 5 mg daily, based on concurrence of 32 [74.4%] and 36 [83.7%] experts, respectively);

Table 3. Consensus Outcomes Regarding How to Treat

| Item | Consensus reached, No. of experts (%) | Round No. |
|---|---------------------------------------|-----------|
| Specialty consultation | | |
| When indicated a specialist from primary care or cardiology may be consulted before prescribing LDOM | 41 (95.3) | 2 |
| Cases when a specialist may be consulted before prescribing LDOM | | |
| A potential precaution is identified | 39 (90.7) | 2 |
| A potential contraindication is identified | 42 (97.7) | 2 |
| Coordination of care is indicated | 41 (95.3) | 2 |
| Baseline testing | | |
| In the absence of precautions, baseline laboratory testing (eg, complete blood count, metabolic panel) is not routinely indicated before LDOM initiation | 39 (90.7) | 2 |
| If a precaution is identified before LDOM initiation, baseline laboratory testing (eg, complete blood count, metabolic panel) may be considered in consultation with a specialist | 32 (74.4) | 2 |
| In the absence of precautions, a baseline electrocardiogram is not routinely indicated before LDOM initiation | 40 (93.0) | 2 |
| If a potential cardiac precaution is identified before LDOM initiation, a baseline electrocardiogram may be considered in consultation with a specialist | 37 (86.0) | 2 |
| Dosing considerations | | |
| Patient characteristics that should be considered when determining the starting dose of LDOM | | |
| Sex | 33 (76.7) | 2 |
| Age | | |
| Adult (≥18 y) | 35 (81.4) | 2 |
| Adolescent (12-17 y) | 36 (83.7) | 2 |
| Hypertrichosis (as either an undesirable or desirable effect) | 40 (93.0) | 2 |
| Risk for systemic adverse effects | 42 (97.7) | 2 |
| Patient characteristics that should be considered when determining the maximum dose of LDOM | | |
| Sex | 35 (81.4) | 3 |
| Adolescent age (12-17 y) | 31 (72.1) | 2 |
| Severity of baseline hair loss | 32 (74.4) | 2 |
| Hypertrichosis (as either an undesirable or desirable effect) | 41 (95.3) | 2 |
| Risk for systemic adverse effects | 41 (95.3) | 2 |
| Most frequently prescribed LDOM starting doses and dosing ranges by patient population | | |
| Female adult | | |
| Starting dose, 1.25 mg daily | 32 (74.4) | 3 |
| Dosing range, 0.625-5 mg daily | 36 (83.3) | 3 |
| Male adult | | |
| Starting dose, 2.5 mg daily | 32 (74.4) | 4 |
| Dosing range, 1.25-5 mg daily | 39 (90.7) | 3 |
| Female adolescent | | |
| Starting dose, 0.625 mg daily | 35 (81.4) | 3 |
| Dosing range, 0.625-2.5 mg daily | 33 (76.7) | 3 |
| Male adolescent | | |
| Starting dose, 1.25 mg daily | 33 (76.7) | 3 |
| Dosing range, 1.25-5 mg daily | 33 (76.7) | 3 |

(continued)

Table 3. Consensus Outcomes Regarding How to Treat (continued)

| Item | Consensus reached, No. of experts (%) | Round No. |
|---|---------------------------------------|-----------|
| Titration | | |
| Patients who are tolerating their current dose of LDOM in the absence of adverse effects can consult with the prescribing clinician about the risks and benefits of a dose increase | 41 (95.3) | 4 |
| Additional agents | | |
| Clinical situations when spironolactone may be coadministered with LDOM in biological female or transgender female patients | | |
| Hirsutism | 39 (90.7) | 2 |
| Acne | 41 (95.3) | 2 |
| Polycystic ovary syndrome or other excess androgen syndrome | 40 (93.0) | 2 |
| Lower extremity edema | 35 (81.4) | 2 |
| Facial edema | 31 (72.1) | 2 |
| β-Blockers may be coadministered with LDOM with specialty consultation | 36 (83.7) | 2 |

Abbreviation: LDOM, low-dose oral minoxidil.

^a These dosing regimens reflect the Low-Dose Oral Minoxidil Initiation (LOMI) expert panel's most frequently used LDOM dosing practices. LOMI experts refrained from providing strict guidelines, specifically regarding upper dosing limits, emphasizing that dosing should be individualized based on patient history and response to therapy.

male adults (starting dose, 2.5 mg daily, and dosing range, 1.25 mg to 5 mg daily, based on concurrence of 32 [74.4%] and 39 [90.7%] experts, respectively); female adolescents (starting dose, 0.625 mg daily, and dosing range, 0.625 mg to 2.5 mg daily, based on concurrence of 35 [81.4%] and 33 [76.7%] experts, respectively); and male adolescents (starting dose, 1.25 mg daily, and dosing range, 1.25 mg to 5 mg daily, based on concurrence of 33 [76.7%] and 33 [76.7%] experts, respectively).

LOMI experts failed to achieve consensus during round 2 on whether LDOM may be considered for pediatric patients with hair loss (23 experts concurred [53.5%]). Pediatric dosing items asked of those experts who noted experience managing pediatric hair loss cases also failed to universally achieve consensus during round 3 (eAppendix and eTable in the [Supplement](#)).

Although specific titration protocols failed to reach consensus during round 2 (eAppendix in the [Supplement](#)), 41 LOMI experts (95.3%) concurred more generally during round 4 that patients tolerating their current dose of LDOM may discuss the risks and benefits of a dose increase with the treating clinician.

Additional Agents

Consensus was strong that spironolactone may be a useful adjunctive agent in biological female or transgender female patients with hirsutism; acne; or polycystic ovary syndrome (or another excess androgen syndrome) (39 experts [90.7%], 41 experts [95.3%], and 40 experts [93.0%] agreed, respectively). LOMI experts also noted during round 2 that spironolactone coadministration may be considered in biological female or transgender female patients when lower extremity edema or facial edema is present (35 [81.4%] and 31 [72.1%] experts agreed, respectively). Consensus was reached that, in the appropriate clinical context, β-blockers may be coadminis-

Table 4. Consensus Outcomes Regarding How to Counsel Patients and Monitor Cases

| Item | Consensus, No. of experts (%) | Round No. |
|---|-------------------------------|-----------|
| Hair shedding and hypertrichosis | | |
| Patients may be counseled that the risk for transient hair shedding with LDOM initiation is likely to be about the same as with topical minoxidil initiation | 32 (74.4) | 2 |
| Patients may be counseled that the risk for hypertrichosis with LDOM is likely to be more significant than with topical minoxidil initiation | 34 (79.1) | 2 |
| Monitoring | | |
| When a precaution has been identified, blood pressure monitoring may be recommended | 39 (90.7) | 2 |
| Cases when adverse effect monitoring may be recommended | | |
| When a precaution has been identified | 42 (97.7) | 2 |
| With LDOM initiation | 40 (93.0) | 2 |
| With LDOM dose escalation | 41 (95.3) | 2 |
| Adverse effects | | |
| Patients can be counseled to monitor for the sequelae of vasodilation: lightheadedness or dizziness and fast or abnormal heartbeat for at least 3-7 d | 34 (79.1) | 4 |
| Patients can be counseled to monitor for the sequelae of salt and fluid retention (ie, swollen feet or legs, facial swelling, weight gain, chest pain, shortness of breath) for at least 4-6 wk | 40 (93.0) | 4 |
| Adverse effects that patients should also be instructed to monitor ^a | | |
| Hypertrichosis | 40 (100) | 2 |
| Headache | 33 (82.5) | 2 |
| Signs of an allergic reaction | 31 (77.5) | 2 |
| Efficacy | | |
| The earliest time point at which LDOM should be expected to demonstrate efficacy is 3 mo | 32 (74.4) | 3 |
| Patients who experience transient hair shedding with LDOM initiation may not note efficacy until 6 mo | 36 (83.7) | 4 |

Abbreviation: LDOM, low-dose oral minoxidil.

^a These items were answered by 40 experts who earlier indicated that adverse effect monitoring was necessary in round 2. The percentages are reflected based on 40 experts' opinions.

tered with LDOM in consultation with a specialist (36 experts [83.7%] concurred; [Table 4](#)).

Consensus Outcomes Regarding How to Counsel and Monitor

Hair Shedding and Hypertrichosis

Consensus was reached in round 2 that the risk for transient hair shedding with LDOM initiation is likely to be similar with topical minoxidil initiation (32 experts concurred [74.4%]), whereas, significant hypertrichosis is more probable with LDOM as compared with topical minoxidil use (24 experts concurred [79.1%]; [Table 4](#)).

Monitoring and Adverse Effects

Blood pressure monitoring may be recommended for patients for whom a precaution has been identified (39 experts [90.7%] concurred). Strong consensus was achieved in round 2 that adverse effect monitoring may be recommended in the following cases: when a precaution has been identified, with LDOM initiation, and with dose

escalation (42 [97.7%], 40 [93.0%], and 41 [95.3%] experts agreed, respectively).

Regarding adverse effects, LOMI experts concurred during round 4 that vasodilation secondary to oral minoxidil occurs acutely and depends on dose with peak effect occurring within 3 to 7 days. Patients can be counseled to monitor for sequelae including light-headedness, dizziness, and fast or abnormal heartbeat (34 experts [79.1%] concurred). They concurred during round 4 that salt and fluid retention secondary to oral minoxidil occurs subacutely/chronically, may be exacerbated by dietary salt intake, concurrent illness, and concomitant medications, and is most likely to present within 4 to 6 weeks. Patients can be counseled to monitor for salt and fluid retention sequelae including swollen feet or legs, facial swelling, weight gain, chest pain, and shortness of breath (40 experts [93.0%] concurred). LOMI experts who agreed that adverse event monitoring is needed (n = 40) reached consensus during round 2 that patients should be counseled to monitor for hypertrichosis when considered an undesirable effect (40 experts concurred [100%]); headache (33 experts concurred [82.5%]); and signs of an allergic reaction (31 [77.5%] experts concurred).

LDOM Efficacy

Consensus was reached in round 4 that the earliest time point at which LDOM should be expected to demonstrate efficacy is 3 months (32 experts concurred [74.4%]). In addition, patients who experience transient hair shedding with LDOM initiation may not note efficacy until 6 months after treatment initiation (36 experts concurred [83.7%]).

LDOM has become a commonly prescribed off-label alternative to topical minoxidil for treating patients with hair loss. This modified Delphi consensus statement involving 43 international hair loss specialists, with a 98% retention rate throughout the survey rounds, provided consensus findings on multiple aspects of LDOM use that may be useful for clinicians given the current lack of prospective data from studies with large sample sizes. These consensus findings addressed specific patient populations, indications, dosing, contraindications, precautions, baseline evaluation, specialty consultation, monitoring, adverse effects, and adjunctive therapy.

The initial survey round, which incorporated non-Likert and Likert scale items, was used to build subsequent rounds. After 4 rounds, 76 items achieved consensus with at least 70% of experts responding agree or strongly agree. It is worth highlighting that 27 of those items readily achieved at least 90% consensus after the first 2 rounds, suggesting broad agreement in practices among experts. The strongest agreement was reached regarding LDOM use in adults with AGA or age-related thinning and in situations when topical minoxidil may be ineffective or challenging. Additionally, strong agreement was reached on dosing considerations and contraindications for patients with potential systemic adverse effects, hypertrichosis, or for those who may be pregnant or nursing. Also, baseline blood pressure level measurement, electrocardiogram re-

sults, and specialty consultations were not recommended by at least 90% of experts when prescribing LDOM unless a precaution was identified. Topics that required more than 2 rounds to reach consensus included dosing ranges, titration, expected efficacy period, and the timeline of adverse events.

Limitations

Limitations of this study included the possibility that experts who were invited but did not participate in the consensus process may have differing opinions on LDOM use for patients with hair loss. Additionally, pediatric hair loss experts were underrepresented on the LOMI expert panel. The lack of consensus on pediatric use and dosing underscores the need for further research in the pediatric population. Furthermore, we did not include patient participation in our consensus process to level-set clinician practices.

The issue of whether oral minoxidil can be safely administered in patients who have true allergic contact dermatitis to topical minoxidil, excluding reactions to nonactive formulary ingredients, is of critical interest. However, the package insert for oral minoxidil does not explicitly address this, stating "minoxidil is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation."⁷ This concern was not adequately resolved by this consensus process. However safe administration of LDOM has been reported in a case series of 9 patients who tolerated oral minoxidil despite a history of acute contact dermatitis attributed to topical minoxidil.³⁵ Until further data are available, a cautious approach can be considered, in which patients who develop cutaneous adverse effects with oral minoxidil should discontinue treatment.³⁵ Topics not addressed by this study but deserving future investigation include the comparative efficacy of topical vs oral minoxidil; the long-term safety of LDOM; and the use of other off-label forms of minoxidil, including compounded formulations of oral minoxidil and sublingual minoxidil, for patients with hair loss.

Considering the evolving landscape surrounding LDOM use, it is imperative to acknowledge that individualized patient needs and responses may vary, and clinicians should exercise their judgment in tailoring LDOM prescriptions and dosing accordingly. As we move forward, these guidelines should serve as a valuable reference but not an exhaustive standard. The authors encourage ongoing research and collaborative efforts to refine and update these recommendations in response to emerging evidence and clinical experience.

Conclusions

This consensus statement contributes substantially to the current understanding of LDOM prescribing for patients with hair loss, providing a solid foundation for clinical practice. These consensus recommendations serve as a crucial reference for dermatologists treating patients with hair loss, offering best-practice insights into LDOM prescribing until further data emerge.

ARTICLE INFORMATION

Accepted for Publication: September 10, 2024.

Published Online: November 20, 2024.
doi:10.1001/jamadermatol.2024.4593

Author Affiliations: George Washington University School of Medicine & Health Sciences, Washington, DC (Akiska); Department of Dermatology, The Permanente Medical Group, Vallejo, California (Mirmirani); Department of Dermatology, University of California, San Francisco

(Roseborough, Mathes, Bhutani, Lester, Fu); Division of Research, Kaiser Permanente Northern California, San Francisco (Ambrosy); Callender Dermatology, Washington, DC (Callender); Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco,

California (Ambrosy); Johns Hopkins School of Medicine, Baltimore, Maryland (Aguh); Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio (Bergfeld); Howard University College of Medicine, Washington, DC (Callender); National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland (Castelo-Soccio); University of Pennsylvania, Philadelphia (Cotsarelis); Yale School of Medicine, New Haven, Connecticut (Craiglow, King); DermDX New England, Sonic Healthcare, Brighton, Massachusetts (Desai, Goldberg); University of São Paulo Medical School, São Paulo, Brazil (Doche); Instituto de Dermatologia Prof Rubem David Azulay, Santa Casa de Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil (Duque-Estrada); Department of Dermatology, The Medical University of South Carolina, Charleston, South Carolina (Elston); University of California, Los Angeles (Goh); Department of Dermatology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts (Goldberg); Universitat Internacional de Catalunya, Barcelona, Spain (Grimalt); Department of Dermatology, University of Iowa, Iowa City, Iowa (Jabbari); Queen Mary University of London, London, United Kingdom (Jolliffe); Iowa City Veterans Affairs Medical Center, Iowa City, Iowa (Jabbari); University of Wisconsin-Madison (LaSenna); Lenzy Dermatology & Hair Loss Center, Chicopee, Massachusetts (Lenzy); Department of Dermatology, University of Connecticut, Farmington (Lenzy); David Tvildiani Medical University, Tbilisi, Georgia (Lortkipanidze); The Ronald O Perelman Department of Dermatology, New York University Langone Health, New York (Lo Sicco); Wake Forest School of Medicine, Winston-Salem, North Carolina (McMichael); Mersey and West Lancashire NHS Trust, St Helens, United Kingdom (Meah); University of California, Irvine (Mesinkovska); Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, Florida (Miteva); Department of Dermatology, Harvard Medical School, Brigham & Women's Hospital, Boston, Massachusetts (Mostaghimi); Department of Infectious Diseases and Clinical Immunology, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine (Ovcharenko); Cleveland Clinic, Cleveland, Ohio (Piliang); Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (Piraccini); Department of Dermatology, Medical University of Warsaw, Warsaw, Poland (Rakowska); Virginia Commonwealth University, Richmond, Virginia (Salkey); Santa Monica Dermatology Group, Santa Monica, California (Schmidt); New York University Grossman School of Medicine, New York (Shapiro); University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada (Sibbald); Sinclair Dermatology, Victoria, Australia (Sinclair); Division of Dermatology, Department of Medicine, Faculty of Medicine, Mahidol University, Ramathibodi Hospital, Bangkok, Thailand (Suchonwanit); Perelman School of Medicine, University of Pennsylvania, Philadelphia (Taylor); University of Miami, Miami, Florida (Tosti); Dermatology Service, Ramon y Cajal Hospital and Grupo Pedro Jaen Clinic, IRYCIS, University of Alcalá, Madrid, Spain (Vaño-Galván); Hair Restoration Blackrock, Dublin, Ireland (Wall); Solano Dermatology Associates, Fairfield, California (Fu); Callendar Cosmetic Center, Baltimore,

Maryland (Callender); Faculty of Biology, Medicine and Health, Manchester University, Manchester, United Kingdom (Meah); Department of Experimental, Diagnostic and Specialty Medicine Alma Mater Studiorum, University of Bologna, Bologna, Italy (Piraccini); University of Melbourne, Melbourne, Victoria, Australia (Sinclair); National and International Skin Registry Solutions (NISR), Belfield, Ireland (Wall); Charles Institute of Dermatology, University College Dublin, Dublin, Ireland (Wall); The Mater Misericordiae University Hospital, Dublin, Ireland (Wall).

Author Contributions: Mr Akiska and Dr Fu had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Akiska, Mirmirani, Mathes, Bergfeld, Elston, Grimalt, Lester, Sinclair, Suchonwanit, Taylor, Tosti, Vaño-Galván, Fu.

Acquisition, analysis, or interpretation of data:

Akiska, Mirmirani, Roseborough, Mathes, Bhutani, Ambrosy, Aguh, Callender, Castelo-Soccio, Cotsarelis, Craiglow, Desai, Doche, Duque-Estrada, Elston, Goh, Goldberg, Jabbari, Jolliffe, King, LaSenna, Lenzy, Lester, Lortkipanidze, Lo Sicco, McMichael, Meah, Mesinkovska, Miteva, Mostaghimi, Ovcharenko, Piliang, Piraccini, Rakowska, Salkey, Schmidt, Shapiro, Sibbald, Sinclair, Suchonwanit, Wall, Fu.

Drafting of the manuscript: Akiska, Mirmirani, Roseborough, Bergfeld, Duque-Estrada, Elston, Mesinkovska, Ovcharenko, Suchonwanit, Fu.

Critical review of the manuscript for important intellectual content: Akiska, Mirmirani,

Roseborough, Mathes, Bhutani, Ambrosy, Aguh, Callender, Castelo-Soccio, Cotsarelis, Craiglow, Desai, Doche, Elston, Goh, Goldberg, Grimalt, Jabbari, Jolliffe, King, LaSenna, Lenzy, Lester, Lortkipanidze, Lo Sicco, McMichael, Meah, Mesinkovska, Miteva, Mostaghimi, Piliang, Piraccini, Rakowska, Salkey, Schmidt, Shapiro, Sibbald, Sinclair, Suchonwanit, Taylor, Tosti, Vaño-Galván, Wall, Fu.

Statistical analysis: Akiska, Ovcharenko, Fu.

Obtained funding: Akiska, Fu.

Administrative, technical, or material support:

Akiska, Mirmirani, Roseborough, Bhutani, Jabbari, Jolliffe, LaSenna, Lester, Mesinkovska, Taylor, Fu. **Supervision:** Akiska, Mirmirani, Mathes, Ambrosy, Bergfeld, Doche, Elston, Grimalt, Lester, Lo Sicco, McMichael, Mostaghimi, Piliang, Piraccini, Shapiro, Tosti, Vaño-Galván, Fu.

Conflict of Interest Disclosures: Dr Mathes reported personal fees from Novartis for consulting on alpelisib for vascular anomalies outside the submitted work. Dr Aguh reported personal fees from Pfizer, Lilly, Myovant Sciences, and a grant from Janssen outside the submitted work. Dr Callender reported honoraria from Aerolase, Beiersdorf, Cutera, Juenes Aesthetics, Ortho Derm, Pfizer, Arcutis, SkinCeuticals, La Roche Posay, and Estée Lauder, grants from AbbVie/Allergan, Avava, Eli Lilly, Incyte, L'Oreal, Prolineum, Symatase, and Teoxane; and personal fees from UpToDate outside the submitted work. Dr Craiglow reported personal fees from AbbVie, Arcutis, Incyte, Eli Lilly, LEO Pharma, GSK, Dermavant, Pfizer, Regeneron, Sanofi-Genzyme, and Sun Pharma outside the submitted work. Dr Doche serves on the Board of Directors of the American Hair Research Society (unpaid) and on the Scientific Advisory Committee of the Scarring Alopecia Foundation (unpaid). Dr Goh reported personal fees from Pfizer and

author fees from *BMJ BestPractices* outside the submitted work. Dr Jabbari reported grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health, the Department of Veterans Affairs, Pfizer, and personal fees from Pfizer, BiologicsMD, Medscape, and UpToDate outside the submitted work. Dr King reported consulting or advisory roles, clinical trial investigation, and data monitoring committee or speaker bureau memberships for multiple companies, including AbbVie, AltruBio, Amgen, AnaptysBio, Bristol Myers Squibb, Concert Pharmaceuticals, Equillum, GSK, Eli Lilly, Incyte, Pfizer, Regeneron, and Sanofi Genzyme. Dr Meah reported personal fees from Pfizer, Eli Lilly, and Dermal outside the submitted work. Dr Mesinkovska reported personal fees from Lilly, Pfizer, Sun Pharma, AbbVie, BiologicsMD, and grants from AbbVie and L'Oreal outside the submitted work. Dr Mostaghimi reported personal fees from hims & hers, AbbVie, Sun Pharma, Pfizer, Digital Diagnostics, Lilly, Equillum, ASLAN, Boehringer Ingelheim, Olaplex, and Legacy Healthcare outside the submitted work. Dr Piliang reported personal fees from Pfizer and Eli Lilly related to Janus kinase inhibitors outside the submitted work. Dr Rakowska gave lectures for Pierre Fabre, L'Oreal, and Arristo. Dr Sinclair reported being the founder, stockholder, and director of Samson Clinical Pty Ltd, which holds several patents in multiple countries. Dr Taylor reported personal fees from AbbVie, Arcutis Biotherapeutics, Beiersdorf, Bristol Myers Squibb, Cara Therapeutics, Catalyst Medical Education, DermSquared, Dior, Eli Lilly, Estée Lauder, Evolus, Galderma, Hugel America, Incyte, L'Oreal, Pfizer, Sanofi, UCB, and Vichy Laboratories, among others, and received stock options from GloGetter and Piction Health and grants from Allergan, Concert Pharmaceuticals, Eli Lilly, and Pfizer. Dr Vaño-Galván reported personal fees from Lilly and Pfizer. Dr Wall reported being a shareholder of Samson Clinical, receiving personal fees from Lilly, Pfizer, Almirall, and Bristol Myers Squibb, and nonfinancial support from Sun Pharma and Tricholab outside the submitted work. Dr Fu reported personal fees from Pfizer, Eli Lilly, and Sun Pharmaceutical outside the submitted work. No other disclosures were reported.

Funding/Support: The University of California, San Francisco, Department of Dermatology, Medical Student Summer Research Fellowship Program provided funding for this work.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

- Phillips TG, Slomiany WP, Allison R. Hair loss: common causes and treatment. *Am Fam Physician*. 2017;96(6):371-378.
- Price VH. Treatment of hair loss. *N Engl J Med*. 1999;341(13):964-973. doi:10.1056/NEJM199909233411307
- Mirmirani P, Fu J. Diagnosis and treatment of nonscarring hair loss in primary care in 2021. *JAMA*. 2021;325(9):878-879. doi:10.1001/jama.2020.19313

4. Lemes LR, Melo DF, de Oliveira DS, de La-Rocque M, Zompero C, Ramos PM. Topical and oral minoxidil for hair disorders in pediatric patients: what do we know so far? *Dermatol Ther*. 2020;33(6):e13950. doi:10.1111/dth.13950
5. Freitas-Martinez A, Shapiro J, van den Hurk C, et al. Hair disorders in cancer survivors. *J Am Acad Dermatol*. 2019;80(5):1199-1213. doi:10.1016/j.jaad.2018.03.056
6. Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. *J Dermatolog Treat*. 2022;33(4):1896-1906. doi:10.1080/09546634.2021.1945527
7. US Food and Drug Administration. Loniten (minoxidil). Pfizer Inc. January 2015. Accessed October 15, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018154s0261bl.pdf
8. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. *J Am Acad Dermatol*. 2021;84(3):737-746. doi:10.1016/j.jaad.2020.06.1009
9. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. *J Am Acad Dermatol*. 2021;84(6):1644-1651. doi:10.1016/j.jaad.2021.02.054
10. Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil treatment for hair loss: a systematic review and pooled-analysis of individual patient data. *Dermatol Ther*. 2020;33(6):e14106. doi:10.1111/dth.14106
11. Sanabria BD, Palmegiani E, Seron AF, Perdomo YC, Miot HA, Müller Ramos P. Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia. *J Am Acad Dermatol*. 2023;88(2):436-437. doi:10.1016/j.jaad.2022.05.026
12. Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. *J Am Acad Dermatol*. 2021;85(3):743-745. doi:10.1016/j.jaad.2019.08.080
13. John JM, Sinclair RD. Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review. *Int J Dermatol*. 2023;62(2):257-259. doi:10.1111/ijd.16373
14. de Nicolas-Ruanes B, Moreno-Arrones OM, Saceda-Corralo D, et al. Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: a descriptive study. *J Am Acad Dermatol*. 2022;87(3):700-702. doi:10.1016/j.jaad.2022.04.030
15. Jackson T, Sow Y, Dinkins J, et al. Treatment for central centrifugal cicatricial alopecia—Delphi consensus recommendations. *J Am Acad Dermatol*. 2024;90(6):1182-1189. Published online February 9, 2024. doi:10.1016/j.jaad.2023.12.073
16. Sanfilippo E, Friedman A. Survey of dermatology practitioners' opinions and prescribing habits of oral minoxidil for the treatment of androgenetic alopecia. *J Drugs Dermatol*. 2024;23(3):136-140.
17. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. *Int J Dermatol*. 2018;57(1):104-109. doi:10.1111/ijd.13838
18. Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study. *F1000Res*. 2017;6:1650. doi:10.12688/f1000research.11775.1
19. Awad A, Chim I, Sharma P, Bhojru B. Low-dose oral minoxidil improves hair density in traction alopecia. *J Am Acad Dermatol*. 2023;89(1):157-159. doi:10.1016/j.jaad.2023.02.024
20. Ong M, Do H, Ho B, Lipner SR. Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study. *J Am Acad Dermatol*. 2024;90(2):425-427. doi:10.1016/j.jaad.2023.10.010
21. Moussa A, Darchini-Maragheh E, Wall D, Meah N, Sinclair R. Low-dose oral minoxidil improves hair length and global hair density in short anagen syndrome. *J Am Acad Dermatol*. 2024;91(2):346-348. Published online April 2024. doi:10.1016/j.jaad.2024.03.040
22. McFeely O, Meah N, Sinclair R, Wall D. Trichorrhexis nodosa improving with oral minoxidil: a case report. *Clin Exp Dermatol*. 2023;48(5):554-555. doi:10.1093/ced/llad019
23. Trüeb RM, Caballero-Urbe N, Luu NC, Dmitriev A. Serious complication of low-dose oral minoxidil for hair loss. *JAAD Case Rep*. 2022;30:97-98. doi:10.1016/j.jdc.2022.09.035
24. Dlova NC, Jacobs T, Singh S. Pericardial, pleural effusion and anasarca: a rare complication of low-dose oral minoxidil for hair loss. *JAAD Case Rep*. 2022;28:94-96. doi:10.1016/j.jdc.2022.07.044
25. Powell C. The Delphi technique: myths and realities. *J Adv Nurs*. 2003;41(4):376-382. doi:10.1046/j.1365-2648.2003.02537.x
26. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. *BMJ Qual Saf*. 2016;25(12):986-992. doi:10.1136/bmjqs-2015-004411
27. Harris PA, Taylor R, Minor BL, et al; REDCap Consortium. The REDCap consortium: building an international community of software platform partners. *J Biomed Inform*. 2019;95:103208. doi:10.1016/j.jbi.2019.103208
28. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. *J Am Acad Dermatol*. 2020;83(1):123-130. doi:10.1016/j.jaad.2020.03.004
29. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. *J Am Acad Dermatol*. 2021;84(6):1594-1601. doi:10.1016/j.jaad.2020.09.028
30. Wall D, Meah N, York K, et al. A global eDelphi exercise to identify core domains and domain items for the development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS). *JAMA Dermatol*. 2021;157(4):1-11. doi:10.1001/jamadermatol.2020.5839
31. Moussa A, Bennett M, Wall D, et al; ASAMI Consensus Survey Study Group. The Alopecia Areata Severity and Morbidity Index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity. *JAMA Dermatol*. 2024;160(3):341-350. doi:10.1001/jamadermatol.2023.5869
32. Spuls PI, Gerbens LAA, Apfelbacher CJ, et al. The International TREATment of ATopic Eczema (TREAT) Registry Taskforce: an initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries. *J Invest Dermatol*. 2017;137(9):2014-2016. doi:10.1016/j.jid.2017.05.014
33. Gerbens LAA, Boyce AE, Wall D, et al. TREATment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. *Trials*. 2017;18(1):87. doi:10.1186/s13063-016-1765-7
34. Gerbens LAA, Apfelbacher CJ, Irvine AD, et al; international TREAT Registry Taskforce. TREATment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries. *Br J Dermatol*. 2019;180(4):790-801. doi:10.1111/bjd.16714
35. Therianou A, Vincenzi C, Tosti A. How safe is prescribing oral minoxidil in patients allergic to topical minoxidil? *J Am Acad Dermatol*. 2022;86(2):429-431. doi:10.1016/j.jaad.2020.04.027